Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03581292




Registration number
NCT03581292
Ethics application status
Date submitted
4/07/2018
Date registered
10/07/2018
Date last updated
21/05/2024

Titles & IDs
Public title
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
Scientific title
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Secondary ID [1] 0 0
NCI-2018-01361
Secondary ID [2] 0 0
NCI-2018-01361
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anaplastic Astrocytoma 0 0
Glioblastoma 0 0
Malignant Glioma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Brain
Cancer 0 0 0 0
Children's - Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - Radiation Therapy
Treatment: Drugs - Temozolomide
Treatment: Drugs - Veliparib

Experimental: Treatment (radiation therapy, veliparib, temozolomide) - CHEMORADIOTHERAPY PHASE: Patients receive veliparib PO BID and undergo 30 daily fractions of radiation therapy 5 days per week for 6-7 weeks in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMOTHERAPY: Beginning 4 weeks after chemoradiotherapy phase, patients receive veliparib PO BID and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.


Treatment: Other: Radiation Therapy
Undergo radiation therapy

Treatment: Drugs: Temozolomide
Given PO

Treatment: Drugs: Veliparib
Given PO
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Event Free Survival (EFS)
Timepoint [1] 0 0
Up to 2 years
Secondary outcome [1] 0 0
Objective Response
Timepoint [1] 0 0
Anytime during treatment (up to 1 year from enrollment)
Secondary outcome [2] 0 0
Overall Survival (OS)
Timepoint [2] 0 0
Up to 2 years

Eligibility
Key inclusion criteria
- Stratum 1 (IDH wild-type): Patients must be >= 3 years of age and =< 21 years of age
at the time of enrollment

- Please note Stratum 1 was closed to accrual on January 24, 2020

- Stratum 2 (IDH mutant): Patients must be >= 3 years of age and =< 25 years of age at
the time of enrollment

- Patients must have eligibility confirmed by rapid central pathology and central
molecular screening reviews performed on APEC14B1:

- Newly-diagnosed high-grade glioma such as anaplastic astrocytoma or glioblastoma

- Negative results for H3 K27M by immunohistochemistry (IHC)

- Negative results for BRAFV600 mutation by next-generation sequencing (NGS)

- Patients must have histological verification of diagnosis. Patients with M+ disease
(defined as evidence of neuraxis dissemination) are not eligible. Cerebrospinal fluid
(CSF) cytology is not required but may be obtained if clinically indicated prior to
study enrollment. If cytology is positive, the patient would be considered to have
metastatic disease and would, therefore, be ineligible

- Pre-operative and post-operative brain magnetic resonance imaging (MRI) with and
without contrast must be obtained. The requirement for a post-operative MRI is waived
for patients who undergo biopsy only. A spine MRI is not required, but may be obtained
if clinically indicated. If the spine MRI is positive, the patient would be considered
to have M+ disease (defined as neuraxis dissemination) and would be ineligible

- Patients must have a performance status corresponding to Eastern Cooperative Oncology
Group (ECOG) scores of 0, 1, or 2. Use Karnofsky for patients > 16 years of age and
Lansky for patients =< 16 years of age

- Peripheral absolute neutrophil count (ANC) >= 1,000/uL (within 7 days prior to
enrollment)

- Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to
enrollment)

- Hemoglobin >= 8.0 gm/dL (can be transfused) (within 7 days prior to enrollment)

- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 OR a serum creatinine based on age/gender as follows (within 7 days
prior to enrollment):

- 3 to < 6 years: 0.8 (male and female) maximum serum creatinine (mg/dL)

- 6 to < 10 years: 1 (male and female) maximum serum creatinine (mg/dL)

- 10 to < 13 years: 1.2 (male and female) maximum serum creatinine (mg/dL)

- 13 to < 16 years: 1.5 (male), 1.4 (female) maximum serum creatinine (mg/dL)

- >= 16 years: 1.7 (male), 1.4 (female) maximum serum creatinine (mg/dL)

- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to
enrollment)

- Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135
U/L. For the purpose of this study, the ULN for SGPT is 45 U/L

- Patients with seizure disorder may be enrolled if seizures are well-controlled (i.e.,
patients must not have required rescue medications for uncontrolled seizures within 14
days prior to enrollment)

- Patients must be enrolled and protocol therapy must be projected to begin no later
than 31 days after definitive surgery (Day 0). If a biopsy only was performed, the
biopsy date will be considered the date of definitive surgery. For patients who have a
biopsy or incomplete resection at diagnosis followed by additional surgery, the date
of the last resection will be considered the date of definitive surgery

- All patients and/or their parents or legal guardians must sign a written informed
consent

- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
Minimum age
3 Years
Maximum age
25 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with the following histologies:

- Diffuse astrocytoma (grade 2)

- Oligodendrogliomas (any grade)

- Pleomorphic xanthoastrocytoma (PXA, any grade)

- Patients with primary tumor location of brainstem or spinal cord

- Patients with M+ disease (defined as neuraxis dissemination either by imaging or by
cytology)

- Patients with treatment-related acute myeloid leukemia (AML) (t-AML)/myelodysplastic
syndrome (MDS) or with features suggestive of AML/MDS

- Prior allogenic bone marrow transplant or double umbilical cord blood transplantation

- Patients must not have received any prior tumor-directed therapy including radiation
therapy, chemotherapy (tumor-directed therapy), molecularly targeted agents, or
immunotherapy for the treatment of HGG other than surgical intervention and/or
corticosteroids

- Lumbar CSF cytology is not required, but may be performed if clinically indicated
prior to study enrollment. If lumbar CSF cytology is positive, the patient is
considered to have M+ disease and is ineligible

- Note: False positive cytology can occur within 10 days of surgery

- Patients with gliomatosis cerebri type 1 or 2

- Patients who are not able to receive protocol specified radiation therapy

- Patients must not be currently receiving other anti-cancer agents

- Patients with known constitutional mismatch repair deficiency syndrome
(CMMR-D)/biallelic mismatch repair deficiency (bMMRD)

- Female patients who are pregnant are ineligible due to risks of fetal and teratogenic
adverse events as seen in animal/human studies

- Lactating females are not eligible unless they have agreed not to breastfeed their
infants

- Female patients of childbearing potential are not eligible unless a negative pregnancy
test result has been obtained

- Sexually active patients of reproductive potential are not eligible unless they have
agreed to use an effective contraceptive method for the duration of their study
participation and for 6 months after the last dose of protocol-specified chemotherapy

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/11/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
22/09/2024
Actual
Sample size
Target
Accrual to date
Final
38
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Recruitment hospital [2] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [3] 0 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [4] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 0 0
Monash Medical Center-Clayton Campus - Clayton
Recruitment hospital [6] 0 0
Royal Children's Hospital - Parkville
Recruitment hospital [7] 0 0
Perth Children's Hospital - Perth
Recruitment postcode(s) [1] 0 0
2310 - Hunter Regional Mail Centre
Recruitment postcode(s) [2] 0 0
2031 - Randwick
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4101 - South Brisbane
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3052 - Parkville
Recruitment postcode(s) [7] 0 0
6009 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Connecticut
Country [7] 0 0
United States of America
State/province [7] 0 0
Delaware
Country [8] 0 0
United States of America
State/province [8] 0 0
District of Columbia
Country [9] 0 0
United States of America
State/province [9] 0 0
Florida
Country [10] 0 0
United States of America
State/province [10] 0 0
Georgia
Country [11] 0 0
United States of America
State/province [11] 0 0
Hawaii
Country [12] 0 0
United States of America
State/province [12] 0 0
Idaho
Country [13] 0 0
United States of America
State/province [13] 0 0
Illinois
Country [14] 0 0
United States of America
State/province [14] 0 0
Indiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Iowa
Country [16] 0 0
United States of America
State/province [16] 0 0
Kentucky
Country [17] 0 0
United States of America
State/province [17] 0 0
Louisiana
Country [18] 0 0
United States of America
State/province [18] 0 0
Maine
Country [19] 0 0
United States of America
State/province [19] 0 0
Maryland
Country [20] 0 0
United States of America
State/province [20] 0 0
Massachusetts
Country [21] 0 0
United States of America
State/province [21] 0 0
Michigan
Country [22] 0 0
United States of America
State/province [22] 0 0
Minnesota
Country [23] 0 0
United States of America
State/province [23] 0 0
Mississippi
Country [24] 0 0
United States of America
State/province [24] 0 0
Missouri
Country [25] 0 0
United States of America
State/province [25] 0 0
Nebraska
Country [26] 0 0
United States of America
State/province [26] 0 0
Nevada
Country [27] 0 0
United States of America
State/province [27] 0 0
New Hampshire
Country [28] 0 0
United States of America
State/province [28] 0 0
New Jersey
Country [29] 0 0
United States of America
State/province [29] 0 0
New York
Country [30] 0 0
United States of America
State/province [30] 0 0
North Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
North Dakota
Country [32] 0 0
United States of America
State/province [32] 0 0
Ohio
Country [33] 0 0
United States of America
State/province [33] 0 0
Oklahoma
Country [34] 0 0
United States of America
State/province [34] 0 0
Oregon
Country [35] 0 0
United States of America
State/province [35] 0 0
Pennsylvania
Country [36] 0 0
United States of America
State/province [36] 0 0
Rhode Island
Country [37] 0 0
United States of America
State/province [37] 0 0
South Carolina
Country [38] 0 0
United States of America
State/province [38] 0 0
South Dakota
Country [39] 0 0
United States of America
State/province [39] 0 0
Tennessee
Country [40] 0 0
United States of America
State/province [40] 0 0
Texas
Country [41] 0 0
United States of America
State/province [41] 0 0
Utah
Country [42] 0 0
United States of America
State/province [42] 0 0
Virginia
Country [43] 0 0
United States of America
State/province [43] 0 0
Washington
Country [44] 0 0
United States of America
State/province [44] 0 0
West Virginia
Country [45] 0 0
United States of America
State/province [45] 0 0
Wisconsin
Country [46] 0 0
Canada
State/province [46] 0 0
Alberta
Country [47] 0 0
Canada
State/province [47] 0 0
British Columbia
Country [48] 0 0
Canada
State/province [48] 0 0
Newfoundland and Labrador
Country [49] 0 0
Canada
State/province [49] 0 0
Nova Scotia
Country [50] 0 0
Canada
State/province [50] 0 0
Ontario
Country [51] 0 0
Canada
State/province [51] 0 0
Quebec
Country [52] 0 0
New Zealand
State/province [52] 0 0
Auckland
Country [53] 0 0
New Zealand
State/province [53] 0 0
Christchurch
Country [54] 0 0
Puerto Rico
State/province [54] 0 0
Caguas

Funding & Sponsors
Primary sponsor type
Government body
Name
National Cancer Institute (NCI)
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in
treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600
mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help
repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so
tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high
energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as
temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib,
radiation therapy, and temozolomide may work better in treating patients with newly diagnosed
malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and
temozolomide alone.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03581292
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Matthias A Karajannis
Address 0 0
Children's Oncology Group
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03581292